Skip to Content

Rasuvo FDA Approval History

FDA Approved: Yes (First approved July 11, 2014)
Brand name: Rasuvo
Generic name: methotrexate
Dosage form: Injection
Previous Name: MPI-2505
Company: Medac Pharma, Inc.
Treatment for: Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis, Psoriasis

Rasuvo (methotrexate) is a subcutaneous, ready-to-use autopen formulation of methotrexate for the treatment of rheumatoid arthritis (RA), poly-articular-course juvenile RA and psoriasis.

Development Timeline for Rasuvo

DateArticle
Jul 14, 2014ApprovalFDA Approves Rasuvo (methotrexate) Injection
Jan 27, 2014Medac Pharma, Inc. Secures FDA Acceptance of a New Drug Application (NDA) for Methotrexate-Containing Autopen

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.